We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA DURAGESIC PEDIATRIC EXCLUSIVITY RULING PROMPTS MYLAN LAWSUIT
FDA DURAGESIC PEDIATRIC EXCLUSIVITY RULING PROMPTS MYLAN LAWSUIT
June 29, 2004
Mylan Pharmaceuticals has sued the FDA over its decision to grant Johnson & Johnson’s (J&J’s) subsidiary Janssen Pharmaceutica six months of pediatric exclusivity on its lucrative pain drug patch Duragesic — a move that will delay generic entry until January 2005.